SNY Financials: Sanofi AI Analysis



Financials

SNY Financial

Sanofi

$44.67

2.57%

$1.12

At close: May 20, 16:00:00 GMT-4

$44.78

0.24%

$0.1

Post-market: May 20, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$43.55

Open

$44.5

Day's Range

$44.3 - $44.82

52 week range

$42.33 - $53.03

Volume

2.6M

Avg.Volume

3.2M

Dividend yield

EPS (TTM)

2.32

Market Cap

$107.2B

What is Sanofi?

Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 84,587 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Features

Markets

News

Breakdown	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025
Revenue	71,130	11,244	25,375	13,170	21,341	--
Revenue Growth (YoY)	--	--	16%	--	7%	--
Cost of Revenue	19,599	3,138	7,168	3,412	5,881	--
Gross Profit	51,531	8,106	18,207	9,758	15,460	--
Selling, General & Admin	14,161	2,327	5,037	2,291	4,506	--
Research & Development	11,423	1,747	4,125	1,834	3,717	--
Operating Expenses	35,273	5,799	12,642	5,889	10,943	--
Other Non Operating Income (Expenses)	49	--	148	--	-99	--
Pretax Income	11,688	2,003	2,593	3,510	3,582	--
Income Tax Expense	2,143	420	332	680	711	--
Net Income	12,229	1,614	2,001	2,802	5,812	--
Net Income Growth	--	--	-40%	--	159%	--
Shares Outstanding (Diluted)	1,204.2	1,204.2	1,219.84	1,218.1	1,231.35	--
Shares Change (YoY)	--	--	-3%	--	-2%	--
EPS (Diluted)	10.15	1.34	1.65	2.31	4.71	--
EPS Growth	--	--	-37%	--	165%	--
Free Cash Flow	10,662	1,683	-93	3,750	364	1,938
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	72.44%	72.09%	71.75%	74.09%	72.44%	--
Operating Margin	22.85%	20.51%	21.93%	29.37%	21.16%	--
Profit Margin	17.19%	14.35%	7.88%	21.27%	27.23%	--
Free Cash Flow Margin	14.98%	14.96%	-0.36%	28.47%	1.7%	--
EBITDA	19,030	2,842	6,564	4,330	5,294	--
EBITDA Margin	26.75%	25.27%	25.86%	32.87%	24.8%	--
D&A For EBITDA	2,772	535	999	461	777	--
EBIT	16,258	2,307	5,565	3,869	4,517	--
EBIT Margin	22.85%	20.51%	21.93%	29.37%	21.16%	--
Effective Tax Rate	18.33%	20.96%	12.8%	19.37%	19.84%	--

Breakdown

TTM

03/31/2026

12/31/2025

09/30/2025

06/30/2025

03/31/2025

Revenue

71,130

11,244

25,375

13,170

21,341

Revenue Growth (YoY)

16%

Cost of Revenue

19,599

3,138

7,168

3,412

5,881

Gross Profit

51,531

8,106

18,207

9,758

15,460

Selling, General & Admin

14,161

2,327

5,037

2,291

4,506

Research & Development

11,423

1,747

4,125

1,834

3,717

Operating Expenses

35,273

5,799

12,642

5,889

10,943

Other Non Operating Income (Expenses)

148

-99

Pretax Income

11,688

2,003

2,593

3,510

3,582

Income Tax Expense

2,143

420

332

680

711

Net Income

12,229

1,614

2,001

2,802

5,812

Net Income Growth

-40%

159%

Shares Outstanding (Diluted)

1,204.2

1,219.84

1,218.1

1,231.35

Shares Change (YoY)

-3%

-2%

EPS (Diluted)

10.15

1.34

1.65

2.31

4.71

EPS Growth

-37%

165%

Free Cash Flow

10,662

1,683

-93

3,750

364

1,938

Free Cash Flow Per Share

Gross Margin

72.44%

72.09%

71.75%

74.09%

72.44%

Operating Margin

22.85%

20.51%

21.93%

29.37%

21.16%

Profit Margin

17.19%

14.35%

7.88%

21.27%

27.23%

Free Cash Flow Margin

14.98%

14.96%

-0.36%

28.47%

1.7%

EBITDA

19,030

2,842

6,564

4,330

5,294

EBITDA Margin

26.75%

25.27%

25.86%

32.87%

24.8%

D&A For EBITDA

2,772

535

999

461

777

EBIT

16,258

2,307

5,565

3,869

4,517

EBIT Margin

22.85%

20.51%

21.93%

29.37%

21.16%

Effective Tax Rate

18.33%

20.96%

12.8%

19.37%

19.84%

Follow-Up Questions

What are Sanofi's key financial statements?



According to the latest financial statement (Form-10K), Sanofi has a total asset of $0, Net loss of $0

What are the key financial ratios for SNY?



Sanofi's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Sanofi's revenue broken down by segment or geography?



Sanofi largest revenue segment is Total Vaccine, at a revenue of 7,936,000,000 in the most earnings release.For geography, United States is the primary market for Sanofi, at a revenue of 22,176,000,000.

Is Sanofi profitable?



no, according to the latest financial statements, Sanofi has a net loss of $0

Does Sanofi have any liabilities?



no, Sanofi has liability of 0

How many outstanding shares for Sanofi?



Sanofi has a total outstanding shares of 0

Sanofi (SNY) Financial

SNY Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Sanofi?

Sanofi (SNY) Financial

SNY Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is Sanofi?

SNY Income

Follow-Up Questions

What are Sanofi's key financial statements?

What are the key financial ratios for SNY?

How is Sanofi's revenue broken down by segment or geography?

Is Sanofi profitable?

Does Sanofi have any liabilities?

How many outstanding shares for Sanofi?